Complement C3 deposition onto bacteria by neonatal serum is not enhanced after the infusion of intravenous immunoglobulin.
To determine the effect of intravenous immunoglobulin (IVIG) on the capacity of serum from septic neonates to deposit complement C3 and IgG onto the bacteria isolated from their blood, 500 mg/kg of IVIG was administered to 18 neonates suspected of being septic. Blood was obtained just before the infusion, and again 15 minutes after its completion. Group B streptococcus type II, group B streptococcus type III, Staphylococcus aureus, and Staphylococcus epidermidis were isolated from the pre-infusion blood of four neonates. Bacteria were incubated with the appropriate serum, washed, and the amount of C3 and IgG subsequently bound to the organisms was quantified by radioimmunobinding assay. Sera from the four septic neonates and sera from four neonates of similar gestational age but whose blood cultures were negative were compared with pooled sera from healthy adults. Before the administration of IVIG, C3 deposition onto the bacteria by sera from five of the seven neonates tested was significantly less than that observed for adult sera. Following the infusion, no increase in C3 deposition was observed for any of the seven sera assayed, and in two cases C3 deposition fell significantly. In contrast, in seven of eight cases, IVIG enhanced the IgG deposition to levels greater than or equal to those observed for adult sera. Therefore, following the infusion of IVIG into neonates with proven or suspected sepsis, the deposition of C3 onto invasive bacteria by their serum was not enhanced even though IgG deposition was increased.
Lassiter
H A
HA
Division of Neonatology, University of Utah School of Medicine, Salt Lake City.
Speranza
M J
MJ
Hall
R T
RT
Meade
V
V
Christensen
R D
RD
Parker
C J
CJ
D000914:Antibodies, Viral / Q000008:administration & dosage* / Q000494:pharmacology; D001419:Bacteria / Q000276:immunology*; D001424:Bacterial Infections / Q000097:blood* / Q000276:immunology / Q000382:microbiology / Q000628:therapy; D003176:Complement C3 / Q000378:metabolism*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D007136:Immunoglobulins / Q000008:administration & dosage* / Q000494:pharmacology; D016756:Immunoglobulins, Intravenous; D007231:Infant, Newborn; D007262:Infusions, Intravenous; D008297:Male; D013211:Staphylococcus aureus / Q000276:immunology; D013212:Staphylococcus epidermidis / Q000276:immunology; D013292:Streptococcus agalactiae / Q000276:immunology
D000914:Antibodies, Viral; D003176:Complement C3; D007074:Immunoglobulin G; D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous